What Are Minor Cannabinoids?
The cannabis plant produces over 100 distinct cannabinoids — yet most clinical and public attention has focused almost entirely on two: THC (tetrahydrocannabinol) and CBD (cannabidiol). The remaining compounds are collectively referred to as minor cannabinoids. While they typically occur in lower concentrations than THC or CBD, their pharmacological activity is by no means minor.
Minor cannabinoids are of growing interest to researchers, clinicians and patients alike — particularly in the context of the entourage effect: the theory that the full spectrum of plant compounds work together synergistically, producing greater therapeutic benefit than any single isolated molecule. Understanding these cannabinoids is therefore central to understanding why different cannabis products produce different effects.
This guide covers the eight most clinically relevant minor cannabinoids, explaining what they are, how they interact with the body, what the current research shows, and — crucially for UK patients — their legal status and availability under the NHS and private prescription system.
The Endocannabinoid System
All cannabinoids — major and minor — exert their effects primarily through the endocannabinoid system (ECS): a widespread biological signalling network present throughout the body.
- CB1 receptors — concentrated in the brain and central nervous system; primarily responsible for psychoactive effects
- CB2 receptors — found mainly in immune tissue and the periphery; associated with inflammation, immune modulation and pain
- Other targets — many cannabinoids also interact with TRP channels, serotonin receptors, PPARgamma and GPR55, giving them effects beyond the classic CB1/CB2 pathway
Different minor cannabinoids have distinct receptor affinities and interaction profiles — which is why they produce such varied effects even though they share a common biosynthetic origin.
Cannabigerol (CBG)
Mother CannabinoidCBG is known as the "mother cannabinoid" because it is the chemical precursor from which all other cannabinoids are synthesised in the cannabis plant. As the plant matures, most CBGA converts into THCA, CBDA or CBCA — which is why CBG typically appears in low concentrations (under 1%) in mature plants. Strains bred specifically to be high in CBG are now available, and early-stage research is exploring its potential therapeutic applications.
How It Works
CBG acts on both CB1 and CB2 receptors of the endocannabinoid system, and also interacts with alpha-2 adrenergic receptors and serotonin receptors. Unlike THC, it does not appear to cause psychoactive effects at therapeutic doses.
Research Summary
Preclinical studies suggest CBG may have anti-inflammatory properties relevant to inflammatory bowel conditions, as well as potential antibacterial activity against resistant strains such as MRSA. Animal studies have explored neuroprotective effects in Huntington's disease models. Human clinical trial data remains limited.
UK Legal Status & Availability
CBG is not scheduled under the Misuse of Drugs Act 1971 in its isolated form, though CBG-dominant cannabis products would be regulated if they also contain controlled cannabinoids. Some licensed UK medical cannabis products contain detectable CBG as a minor constituent.
Cannabinol (CBN)
Sleep & SedationCBN forms when THC oxidises — essentially, it is aged or degraded THC. Cannabis that has been stored for prolonged periods typically contains higher CBN concentrations. It has a mild psychoactive profile, estimated at roughly one-tenth the potency of THC, and is most associated with sedative and sleep-supportive effects, making it one of the more clinically interesting minor cannabinoids.
How It Works
CBN acts as a weak agonist at CB1 and CB2 receptors. It also interacts with TRPV channels and has been shown to inhibit potassium currents in sensory neurons, which may contribute to its analgesic properties. Its sedative reputation is largely anecdotal but is supported by some preclinical evidence.
Research Summary
A 2021 study published in Psychopharmacology found that CBN alone did not significantly alter sleep parameters, but in combination with CBD showed enhanced sedative effects — suggesting the entourage effect may be relevant here. Research into CBN for pain, glaucoma (via reduced intraocular pressure) and appetite stimulation is ongoing.
UK Legal Status & Availability
CBN is listed as a Class B controlled substance in the UK under the Misuse of Drugs Act 1971. It is present as a trace constituent in some licensed medical cannabis flower products.
Tetrahydrocannabivarin (THCV)
Appetite & EnergyTHCV is structurally similar to THC but has a propyl rather than pentyl side chain, giving it distinct pharmacological properties. At lower doses it acts as a CB1 receptor antagonist — suppressing appetite rather than stimulating it — while at higher doses it may become a weak agonist, producing mild psychoactive effects. It is associated with fast-onset, clear-headed, energising effects and is found in higher concentrations in some Central Asian and African landrace strains.
How It Works
At sub-threshold doses THCV antagonises CB1 receptors (blocking THC's appetite-stimulating effect), while at higher doses it acts as a partial CB1 agonist. It is also a potent CB2 receptor agonist. THCV activates TRPV1 channels and may modulate glycaemic control through pancreatic effects.
Research Summary
A 2016 clinical study published in Diabetes Care found that THCV improved fasting glucose, adiponectin levels and pancreatic beta-cell function in patients with type 2 diabetes. Research into THCV for obesity, Parkinson's disease and epilepsy is also underway. It remains one of the more scientifically studied minor cannabinoids.
UK Legal Status & Availability
THCV is a Class B controlled substance in the UK. It appears in trace amounts in many licensed UK medical cannabis products, particularly some African-heritage sativa strains.
Cannabichromene (CBC)
Anti-inflammatoryCBC is the third most prevalent cannabinoid in most cannabis varieties (after THC and CBD) yet remains far less studied. It is non-psychoactive and is produced from CBCA, itself derived from CBGA. CBC is thought to contribute significantly to the entourage effect, working synergistically with THC and CBD to enhance overall therapeutic outcomes. It is particularly abundant in tropical cannabis varieties.
How It Works
Unlike most cannabinoids, CBC does not bind strongly to CB1 or CB2 receptors. Instead, it primarily interacts with TRPA1 and TRPV1 channels — transient receptor potential channels involved in pain signalling — and inhibits the uptake of anandamide, the body's natural endocannabinoid.
Research Summary
A 2011 study found that CBC promoted neurogenesis (the growth of new brain cells) in adult neural stem progenitor cells. Other preclinical research points to anti-inflammatory effects distinct from those of CBD, suggesting the two cannabinoids may act on different inflammatory pathways. CBC has also shown potential antidepressant activity in animal models when combined with THC.
UK Legal Status & Availability
CBC is not individually scheduled in UK law, though it is present as a minor constituent in licensed medical cannabis products. Most licensed flower and oil products contain CBC at concentrations under 0.5%.
Delta-8 THC (D8-THC)
Strictly ControlledDelta-8 THC is a structural isomer of Delta-9 THC — the primary psychoactive cannabinoid in cannabis — differing only in the position of a double bond. It occurs naturally in very small quantities in the cannabis plant but is typically produced commercially via chemical conversion from CBD. It is reported to produce milder psychoactive effects than Delta-9 THC, with some users describing it as clearer and less anxiety-inducing.
How It Works
Delta-8 THC binds to CB1 receptors in the brain in the same manner as Delta-9 THC, producing psychoactive effects, though with lower binding affinity. The milder subjective profile is thought to result from this reduced receptor affinity rather than a fundamentally different mechanism of action.
Research Summary
Research is limited relative to Delta-9 THC. A 1995 study in children with cancer found that Delta-8 THC completely prevented chemotherapy-induced vomiting with minimal side effects — a noteworthy result. More recent interest has focused on its potential as an antiemetic and neuroprotective agent, though robust clinical trials are lacking.
UK Legal Status & Availability
Delta-8 THC is a Class B controlled substance in the UK and subject to the same legal restrictions as Delta-9 THC. Unlike the United States — where a regulatory grey area led to widespread over-the-counter sales — Delta-8 products are not legally available in UK retail settings. It may appear in trace amounts in some licensed medical cannabis products.
Cannabidiolic & Cannabigerolic Acid (CBDA/CBGA)
Raw Acidic FormsCBDA and CBGA are the raw, acidic precursors to CBD and CBG respectively. They are present in fresh, uncured cannabis and are converted to their neutral forms through decarboxylation — the process of heating. Raw cannabis preparations such as cold-pressed oils or tinctures made from fresh plant material may retain CBDA and CBGA. While often overlooked, these acidic cannabinoids have distinct pharmacological profiles from their decarboxylated counterparts.
How It Works
CBDA is a potent serotonin 5-HT1A receptor agonist — with roughly 100-fold greater affinity than CBD — which may explain its strong anti-nausea and anti-emetic properties. It also inhibits the COX-2 enzyme (a target of ibuprofen and aspirin), suggesting anti-inflammatory activity. CBGA inhibits COX-1 and COX-2 enzymes and has shown preliminary activity against the SARS-CoV-2 spike protein in laboratory studies.
Research Summary
A 2020 study led by GW Pharmaceuticals found CBDA dramatically reduced nausea in animal models, performing better than CBD alone. Research into CBGA has highlighted potential anti-diabetic properties via inhibition of aldose reductase. Both acidic cannabinoids remain early-stage research targets with promising but not yet clinically proven profiles.
UK Legal Status & Availability
CBDA is not separately scheduled in the UK. CBGA is also unscheduled in isolated form. However, products derived from cannabis plants containing controlled cannabinoids remain subject to cannabis regulations regardless of the individual constituent present.
Tetrahydrocannabinolic Acid (THCA)
Non-psychoactive PrecursorTHCA is the non-psychoactive acidic precursor to THC found in raw, live cannabis. The plant produces THCA, not THC directly — it is only when THCA is heated (smoked, vaporised, or baked) that it undergoes decarboxylation and converts to the psychoactive Delta-9 THC. This means raw cannabis or unheated THCA preparations do not produce a "high," yet THCA itself appears to carry significant therapeutic properties.
How It Works
THCA does not bind significantly to CB1 receptors (hence no psychoactivity), but instead interacts with TRPA1 and TRPM8 channels, inhibits COX-1 and COX-2 enzymes, and activates PPARgamma — a nuclear receptor with roles in metabolic regulation and inflammation. Its anti-inflammatory activity is thought to be mediated primarily through COX inhibition.
Research Summary
Preclinical research has shown THCA to reduce neuroinflammation in mouse models of Parkinson's disease and to exhibit anti-proliferative effects on prostate cancer cells in vitro. A 2017 study found THCA reduced nausea and vomiting in animal models, suggesting potential as an antiemetic distinct from THC. Human data is currently limited to anecdotal reports and early observational work.
UK Legal Status & Availability
THCA is a controlled substance in the UK. Despite being non-psychoactive itself, it is listed as a Class B drug under the Misuse of Drugs Act 1971 because of its direct conversion to THC on heating. Unheated cannabis containing THCA is therefore still controlled. THCA is present as the dominant cannabinoid in licensed medical cannabis flower before vaporisation.
Minor Cannabinoids in UK Licensed Medical Cannabis
UK medical cannabis products are licensed as whole-plant preparations, meaning that even a product labelled primarily as a "THC flower" or "CBD oil" will contain a broader profile of cannabinoids. The table below summarises the typical presence and legal status of each minor cannabinoid within the UK medical cannabis framework.
| Cannabinoid | Typically Found in UK Products | UK Controlled? | Research Stage |
|---|---|---|---|
| CBG | Yes — minor constituent in most full-spectrum flower and oils | No (in isolation) | Preclinical |
| CBN | Yes — trace amounts, especially in aged or oxidised flower | Yes — Class B | Preclinical / Early clinical |
| THCV | Yes — in some sativa-dominant strains | Yes — Class B | Phase II clinical trials |
| CBC | Yes — minor constituent in most flower products | No (in isolation) | Preclinical |
| Delta-8 THC | Trace amounts only; not commercially present | Yes — Class B | Limited clinical |
| CBDA | Minimal — only in undecarboxylated preparations | No (in isolation) | Preclinical |
| CBGA | Minimal — only in undecarboxylated preparations | No (in isolation) | Preclinical |
| THCA | Yes — dominant form in unvaporised flower | Yes — Class B | Preclinical |
Patients with a specific interest in a particular minor cannabinoid should discuss this with their prescribing clinician, who can advise on strain selection and product formulation to maximise the relevant cannabinoid profile within their treatment plan.
Frequently Asked Questions
What are minor cannabinoids?
Are minor cannabinoids legal in the UK?
Can I access minor cannabinoids through a UK medical cannabis prescription?
Does CBG get you high?
What is the entourage effect and why does it matter for minor cannabinoids?
Is Delta-8 THC available to buy in UK shops?
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. The research cited reflects preclinical and early clinical findings; it does not imply that any cannabinoid is licensed or approved for treating any condition in the UK. Always consult your prescribing clinician or specialist before making any decisions about your medical cannabis treatment. Full disclaimer · Patient Guides